Ananda Arumugam1, Noor Azman A Rahman2, Sharon Casilda Theophilus2, Ashraf Shariffudin2, Jafri Malin Abdullah3. 1. Department of Neurosurgery, Hospital Queen Elizabeth II, PO Box 2029, 88586 Sabah, Malaysia. 2. Department of Neurosurgery, Hospital Sultanah Aminah, Jalan Persiaran Abu Bakar Sultan, 80100 Johor Bharu, Johor, Malaysia. 3. Center for Neuroscience Services & Research, Universiti Sains Malaysia, 16150 Kubang Kerian, Kelantan, Malaysia.
Abstract
BACKGROUND:Mortality and morbidity associated with intracerebral hemorrhage is still high. Up to now, there are no evidence-based effective treatments for acute ICH. This study is to assess the effect of tranexamic acid (TXA) on hematoma growth of patients with spontaneous ICH compared to a placebo. METHODS: We performed a single-blinded, randomised placebo-controlled trial of TXA (intravenous 1g bolus, followed by infusion TXA 1 g/hour for 8 hours) in acute (< 8 hours) primary ICH. Strict blood pressure control (target SBP 140-160 mmHg). A repeat Computed Tomography brain was done after 24 hours to reassess hematoma growth. The primary objective is to test the effect of TXA on hematoma growth. Other objective was to test the feasibility, tolerability, and adverse events of TXA in primary ICH. RESULTS: Statistical analysis showed significant hematoma growth in control group after 24 hours compared to baseline (14.3300 vs 17.9940, P = 0.001) whereas the treatment group there is no significant hematoma size expansion between baseline and after 24 hours (P = 0.313). CONCLUSIONS: This study showed a significant hematoma volume expansion in the control group compared to the treatment group.
RCT Entities:
BACKGROUND: Mortality and morbidity associated with intracerebral hemorrhage is still high. Up to now, there are no evidence-based effective treatments for acute ICH. This study is to assess the effect of tranexamic acid (TXA) on hematoma growth of patients with spontaneous ICH compared to a placebo. METHODS: We performed a single-blinded, randomised placebo-controlled trial of TXA (intravenous 1g bolus, followed by infusion TXA 1 g/hour for 8 hours) in acute (< 8 hours) primary ICH. Strict blood pressure control (target SBP 140-160 mmHg). A repeat Computed Tomography brain was done after 24 hours to reassess hematoma growth. The primary objective is to test the effect of TXA on hematoma growth. Other objective was to test the feasibility, tolerability, and adverse events of TXA in primary ICH. RESULTS: Statistical analysis showed significant hematoma growth in control group after 24 hours compared to baseline (14.3300 vs 17.9940, P = 0.001) whereas the treatment group there is no significant hematoma size expansion between baseline and after 24 hours (P = 0.313). CONCLUSIONS: This study showed a significant hematoma volume expansion in the control group compared to the treatment group.
Authors: Adnan I Qureshi; Ricardo A Hanel; Jawad F Kirmani; Abutaher M Yahia; L Nelson Hopkins Journal: Neurosurg Clin N Am Date: 2002-07 Impact factor: 2.509
Authors: Lewis B Morgenstern; J Claude Hemphill; Craig Anderson; Kyra Becker; Joseph P Broderick; E Sander Connolly; Steven M Greenberg; James N Huang; R Loch MacDonald; Steven R Messé; Pamela H Mitchell; Magdy Selim; Rafael J Tamargo Journal: Stroke Date: 2010-07-22 Impact factor: 7.914
Authors: Adnan I Qureshi; Shahram Majidi; Waqas I Gilani; Yuko Y Palesch; Renee Martin; Jill Novitzke; Salvador Cruz-Flores; Asad Ehtisham; Joshua N Goldstein; Jawad F Kirmani; Haitham M Hussein; M Fareed K Suri; Nauman Tariq Journal: Neurocrit Care Date: 2014-06 Impact factor: 3.210
Authors: Joseph Broderick; Sander Connolly; Edward Feldmann; Daniel Hanley; Carlos Kase; Derk Krieger; Marc Mayberg; Lewis Morgenstern; Christopher S Ogilvy; Paul Vespa; Mario Zuccarello Journal: Circulation Date: 2007-10-16 Impact factor: 29.690
Authors: Zhe Kang Law; Atte Meretoja; Stefan T Engelter; Hanne Christensen; Eugenia-Maria Muresan; Solveig B Glad; Liping Liu; Philip M Bath; Nikola Sprigg Journal: Eur Stroke J Date: 2016-10-26